180 related articles for article (PubMed ID: 21705982)
1. Bone disease in thalassaemia major: recent advances in pathogenesis and clinical aspects.
Skordis N; Toumba M
Pediatr Endocrinol Rev; 2011 Mar; 8 Suppl 2():300-6. PubMed ID: 21705982
[TBL] [Abstract][Full Text] [Related]
2. Hormonal dysregulation and bones in thalassaemia--an overview.
Skordis N; Efstathiou E; Kyriakou A; Toumba M
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():107-15. PubMed ID: 19337163
[TBL] [Abstract][Full Text] [Related]
3. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia.
Voskaridou E; Terpos E
Br J Haematol; 2004 Oct; 127(2):127-39. PubMed ID: 15461618
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in the prevalence and severity of bone disease in thalassaemia.
Kyriakou A; Savva SC; Savvides I; Pangalou E; Ioannou YS; Christou S; Skordis N
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():116-22. PubMed ID: 19337164
[TBL] [Abstract][Full Text] [Related]
5. Endocrine complications in patients with Thalassaemia Major.
Toumba M; Sergis A; Kanaris C; Skordis N
Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment.
De Sanctis V; Soliman AT; Elsedfy H; Yassin M; Canatan D; Kilinc Y; Sobti P; Skordis N; Karimi M; Raiola G; Galati MC; Bedair E; Fiscina B; El Kholy M;
Pediatr Endocrinol Rev; 2013 Dec; 11(2):167-80. PubMed ID: 24575552
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
[TBL] [Abstract][Full Text] [Related]
8. The multifactorial origin of growth failure in thalassaemia.
Skordis N; Kyriakou A
Pediatr Endocrinol Rev; 2011 Mar; 8 Suppl 2():271-7. PubMed ID: 21705977
[TBL] [Abstract][Full Text] [Related]
9. The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis.
Morabito N; Russo GT; Gaudio A; Lasco A; Catalano A; Morini E; Franchina F; Maisano D; La Rosa M; Plota M; Crifò A; Meo A; Frisina N
Bone; 2007 Jun; 40(6):1588-94. PubMed ID: 17412659
[TBL] [Abstract][Full Text] [Related]
10. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis in beta-thalassemia: Clinical and genetic aspects.
Origa R; Fiumana E; Gamberini MR; Armari S; Mottes M; Sangalli A; Paglietti E; Galanello R; Borgna-Pignatti C
Ann N Y Acad Sci; 2005; 1054():451-6. PubMed ID: 16339696
[TBL] [Abstract][Full Text] [Related]
12. Low bone mineral density in adolescents with beta-thalassemia.
Vogiatzi MG; Autio KA; Mait JE; Schneider R; Lesser M; Giardina PJ
Ann N Y Acad Sci; 2005; 1054():462-6. PubMed ID: 16339698
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and management of osteoporosis in thalassemia.
Voskaridou E; Terpos E
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():86-93. PubMed ID: 19337161
[TBL] [Abstract][Full Text] [Related]
14. Osteoporosis syndrome in thalassaemia major: an overview.
Toumba M; Skordis N
J Osteoporos; 2010 May; 2010():537673. PubMed ID: 20976089
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density in Iranian adolescents and young adults with beta-thalassemia major.
Shamshirsaz AA; Bekheirnia MR; Kamgar M; Pakbaz Z; Tabatabaie SM; Bouzari N; Pourzahedgilani N; Azarkeivan A; Hashemi SR; Moosavi F; Alebouyeh M; Vosough P; Kimiagar M; Shamshirsaz AA; Moradi M; Habibzadeh MR; Nobakhthaghighi N; Larijani B
Pediatr Hematol Oncol; 2007; 24(7):469-79. PubMed ID: 17786783
[TBL] [Abstract][Full Text] [Related]
16. Growth and puberty in thalassemia major.
Raiola G; Galati MC; De Sanctis V; Caruso Nicoletti M; Pintor C; De Simone M; Arcuri VM; Anastasi S
J Pediatr Endocrinol Metab; 2003 Mar; 16 Suppl 2():259-66. PubMed ID: 12729401
[TBL] [Abstract][Full Text] [Related]
17. Growth factors and bone formation in osteoporosis: roles for IGF-I and TGF-beta.
Marie P
Rev Rhum Engl Ed; 1997 Jan; 64(1):44-53. PubMed ID: 9051859
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients.
Salah H; Atfy M; Fathy A; Atfy M; Mansor H; Saeed J
Immunol Invest; 2010; 39(8):820-32. PubMed ID: 20718662
[TBL] [Abstract][Full Text] [Related]
19. Use of hormone replacement therapy for correction of high turnover bone disease in hypogonadal β-Thalassemia major patients presenting with osteoporosis: comparison with idiopathic premature ovarian failure.
Chatterjee R; Katz M; Bajoria R
Hemoglobin; 2011; 35(5-6):653-8. PubMed ID: 22074125
[TBL] [Abstract][Full Text] [Related]
20. [Growth and endocrine function in major thalassemia].
Pérignon F; Brauner R; Souberbielle JC; de Montalembert M; Girot R
Arch Fr Pediatr; 1993 Oct; 50(8):657-63. PubMed ID: 8002739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
